Androgens in menopausal women;Andrógenos en la mujer menopáusica

Medicina Clinica

Volumn 120, Issue 1, 2003, Pages 31-36

  Pérez López, Faustino R ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; APOLIPOPROTEIN; BETA ENDORPHIN; CORTICOTROPIN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TIBOLONE;

ACNE; ADULT; ANOVULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; COGNITION; EDEMA; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; MENOPAUSAL SYNDROME; MOTIVATION; OSTEOLYSIS; OVARY FUNCTION; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK MANAGEMENT; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUALITY; SYMPTOM; VIRILIZATION;

EID: 0037452297     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042011     Document Type: Review

References (97)

1. Pettersson K, Gustafsson J-Å. Role of estrogen receptor beta in estrogen action. Annu Rev Physiol 2001;63:165-92.
2. Pérez-López FR. THS con andrógenos. Ponencias del Congreso VII Congreso de la Asociación Española para el Estudio de la Menopausia; 2002, mayo 14-17, 76-8.
3. Hammond GL, Hirvonen J, Vihko R. Progesterone, androstenedione, testosterone, 5 alpha-dihydrotestosterone and androsterone concentrations in specific regions of the human brain. J Steroid Biochem 1983;18:185-9.
4. Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgenes promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 1999;61:353-7.
5. Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landén M, Jansson M, et al. Polymorphisms of the androgen receptor gene and the estrogen receptor [beta] gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001;86:2562-8.
6. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995;80:1429-30.
7. Carlstrom K, Brody S, Lunell NO, Lagrelius A, Mollerstrom G, Pousette A, et al. Dehydroepiandrosterone sulphate and dehydroepiandrosterone in serum: differences related to age and sex. Maturitas 1988;10:297-306.
8. Ravaglia G, Forti P, Maioli F, Boschi F, Bernardi M, Pratelli L, et al. The relationship of dehydroepiandrosterone sulphate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over ninety-years-olds. J Clin Endocrinol Metab 1996;81:1173-8.
9. Meldrum DR. Changes in circulating steroids with aging in post menopausal women. Obstet Gynecol 1997;57:624-8.
10. Davis SR, Burger HG. Androgens and the postmenopausal woman. J Clinical Endocrinol Metab 1996;81:2759-64.
11. Rittmaster RS. Clinical relevance of testosterone and dihydrotestosterone metabolism in women. Am J Med 1995;98(Suppl 1A):17-21.
12. McKenna TJ, Fearon U, Clarke D, Cunningham SK. A critical review of the origin and control of adrenal androgens. Baillière's Clin Obstet Gynaecol 1997;11:229-48.
13. Simon J, Klaiber E, Witta B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999;6:138-46.
14. Burger HG, Dudley EC, Cui J, Dennerstein L, hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 2000;85:2832-8.
15. Slater CC, Zhang C, Hodis HN, Mack WJ, Boostanfar R, Shoupe D, et al. Comparison of estrogen and androgen levels after oral estrogen replacement therapy. J Reprod Med 2001;46:1052-6.
16. Mathur RS, Landgreve SC, Moody LO, Semmens JP, Williamson HO. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas 1985;7:129-33.
17. Davis S. Do androgens or estrogens drive libido? Conferencia de Expertos: Setting a new standard in HRT: The tissue-specific approach; 2001, junio 7-10;Budapest.
18. Wallen K, Eisler JA, Tannenbaum PL, Nagell KM, Mann DR. Antide (Nal-Lys GnRH antagonist) suppression of pituitary-testicular function and sexual behaviour in group-living rhesus monkeys. Physiol Behav 1991;50: 429-35.
19. Feder HH. Hormones and sexual behaviour. Annu Rev Psychol 1984;35: 165-200.
20. Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 1992; 75:1503-7.
21. Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ. Effects of endogenous testosterone and estradiol on sexual behaviour in normal young men. J Clin Endocrinol Metab 1994;78:711-6.
22. Dabbs JM Jr, Mohammed S. Male and female salivary testosterone concentrations before and after sexual activity. Phisiol Behaviour 1992;52: 195-7.
23. Kaplan HS, Owett T. The female androgen deficiency syndrome. J Sex Marital Ther 1993;19:3-24.
24. Bachmann GA, Leiblum SR, Kemmann E, Colburn DW, Swartzman L, Shelden R. Sexual expression and its determinants in the post-menopausal woman. Maturitas 1984;6:19-29.
25. Cutler WB, Garcia C-R, huggins GR, Preti G. Sexual behaviour and steroid levels among gynecologically premature premenopausal women. Fertil Steril 1986;48:496-502.
26. Schreiner-Engel P, Schiavi RC, White D, Ghizzani A. Low sexual desire in women: the role of reproductive hormones. Horm Behav 1989;23:221-34.
27. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-8.
28. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44.
29. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47:339-51.
30. Sherwin BB. Androgen use in women. En: Bhasin S, Gabelnick H, Spieler JM, Swerdloff RS, Wang C, editors. Pharmacology, biology, and clinical applications of androgens. New York: Wiley-Liss, 1996; p. 319-24.
31. Davis SR, McCloud PI, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on posmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
32. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. J Reprod Med 1998;43:847-56.
33. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
34. Castelo-Branco C, Vicente JJ, Figueras F, Sanjuán A, Martínez de Osaba MJ, Casals E, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexually in postmenopausal women. Maturitas 2000;34:161-8.
35. Sands RH, Studd JW, Jones J, Alaghband-Zadeh J. Comparison of the biochemical effects of testosterone and estrogen on bone markers in surgically menopausal women. Gynecol Endocrinol 2000;14:382-7.
36. Khastgir G, Studd J. Hysterectomy, ovarian failure, and depression. Menopause 1998;5:113-22.
37. Sherwin BB, Gelfand MM. Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in surgical menopause. Am J Obstet Gynecol 1984;148:552-7.
38. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-7.
39. Christiansen K, Hars O. Normale alterungsprozesse bei frauen und manner: Ist der verminderte dehydroepiandrosteron (DHEA)-spiegel blosse koinzidenz oder ursache? En: Schultz M, Christiansen H, Griel H, Henke W, editors. Schnittstelle mensch-umwelt in vergangenheit, gegenvart und zukunft. Göttingen: Cuvillier, 2000; p. 132-5.
40. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360-7.
41. Ginsberg J, Swinhoe J, O'Reilly B. Cardiovascular responses during the menopausal hot flush. Br J Obstet 1981;88:925-30.
42. Rebar RW, Spitzer IB. The physiology and measurements of hot flushes. Am J Obstet Gynecol 1987;156:1284-8.
43. Kronenberg F, Cole LJ, Linkie DM, Dyrenfurth I, Downey JA. Menopausal hot flushes: thermoregulatory cardiovascular and circulating catecholamine and LH changes. Maturitas 1984;6:3-43.
44. Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin releasing hormone male contraceptive. N Engl J Med 1981;305:663-7.
45. Ginsburg J, O'Reilly B. Climacteric flushing in a man. BMJ 1983; 287:262.
46. Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N. The management of persistent menopausal symptoms with estradiol-testosterone implants. Clinical, lipid, and hormonal results. Maturitas 1984;6: 351-8.
47. Ballinger CB, Browning MCK, Smith AHW. Hormone profiles and psychological symptoms in perimenopausal women. Maturitas 1987;9:235-51.
48. Bachmann G. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:312-6.
49. Øverlie I, Moen MH, Holte A, Finset A. Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas 2002;41:69-77.
50. Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990;70: 1124-31.
51. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey IJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. Obst Gynecol 1995;85:529-37.
52. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999;44: 1012-20.
53. Chesnut CH III, Nelp WB, Baylink DJ. Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass. Metabolism 1977;26:267-77.
54. Buchanan JR, Hospodar P, Myers C, Leuenberger P, Demers LM. Effects of excess endogenous androgens on bone density in young women. J Clin Endocrinol Metab 1988;67:937-43.
55. Kasperk C, Helmboldt A, Borcsok J, Heuthe S, Cloos O, Niethard F, et al. Skeletal site dependent expressions of the androgen receptor in human osteoblastic cell populations. Calcif Tissue Int 1997;61:464-73.
56. Lea CK, Flanagan AM. Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat. AJP Endo 1998;274:E328-35.
57. Need GA, Horowitz M, Bridges A, Morris HA, Nordin BEX. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic women. Arch Intern Med 1989;149:57-60.
58. Erdtsieck RJ, Pols HAB, Van Kuijk C, Birkenhager-Frenkel DL, Zeelenberg J, Kooy PP, et al. Course of bone mass during and afer hormonal replacement therapy without and with addition of nandrolone decanoate. J Bone Miner Res 1994;9:277-83.
59. Raisz LG, Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996;81:37-43.
60. Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induces growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil Steril 2001;76:241-8.
61. Baulieu E, Thomas G, Legrain S, Lahlou N, Roger N, Debuire B. Dehydroepiandrosterone (DHEA), DHEA suphate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279-84.
62. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of 6-months treatment with a 100 mg daily dose of DHEA on circulating sex steroids, body composition, and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998;49:421-32.
63. Pérez-López FR. Obesidad, climaterio y tratamiento hormonal de reemplazo. Boletín Asociación Española para el Estudio Menopausia 2001;3: 7-12.
64. Espeland MA, Stefanick ML, Kritz-Silverstein D, Fingberg SE, Waclawiw MA, James MK, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. J Clin Endocrinol Metab 1997;82: 1549-56.
65. O'Sullivan AJ, Crampton LJ, Freund J, Ho KKY. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 1998;102: 1035-40.
66. Lovejoy JC, Bray GA, Bourgeois MO, Macchiavelli R, Rood JC, Greeson C, et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women-a clinical research center study. J Clin Metab 1996;81:2198-203.
67. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effect of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metabol 2002;87:1509-16.
68. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravniker V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204.
69. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, et al. Ethynyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994; 89:52-60.
70. Crook D. Perfil del riesgo cardiovascular en la mujer postmenopáusica bajo tratamiento hormonal de reemplazo. En: Pérez-Lóprez FR, editor. Climaterio y envejecimiento: medicina basada en la evidencia. Zaragoza: SEISGE, 1999; p. 117-27.
71. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al, for the Heart and Estrogen/progestin Replacement Study (HERBS) reearch group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;289:605-13.
72. Adams MR, Williams JK, Kaplan JR. Effects of androgens on coronary therosclerosis and atherosclerosis related impairement of vascular response. Arterio Thromb Vasc Biol 1995;15:562-70.
73. Wagner JD, Zhang L, Williams JK, Register TC, Ackerman DM, Wiita B, et al. Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys. Arterio Throm Vasc Biol 1996;16:1473-80.
74. Sherwin BB, Gelfand MM, Schucher R, Gabor J. Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations. Am J Obstet Gynecol 1987;156:414-9.
75. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993;82:919-24.
76. Simon JA. Safety of estrogen/androgen regimens. J Reprod Med 2001; 46(3 Suppl):281-90.
77. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001;86:158-61.
78. Pérez-López FR. Distrofias vulvares y vulvodinia. En: Pérez-López FR, editor. Climaterio y envejecimiento: medicina basada en la evidencia. Zaragoza: SEISGE, 1999; p. 355-72.
79. Booij A, Biewenga-Booij CM, Huber-Bruning O, Cornelis C, Jacobs JWG, Bijlsma JW. Androgens as adjuvant treatment in postmenopausal women female patients with rheumatoid arthritis. Ann Rheum Dis 1996;55: 811-86.
80. Van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematous with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998;25:285-9.
81. Wilder RL. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J Rheumatol 1996;44(Suppl):102.
82. Dorgan JF, Longcope C, Stanczk FZ, Stephenson HE, Hoover RN Jr. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:380-1.
83. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies. J Natl Cancer Inst 2002; 94:606-16.
84. Wang DY, Allen DS, De Stavola BL, Fentiman IS, Brussen J, Bulbrook RD, et al. Urinary androgens and breast cancer risk; results from a long-term prospective study bases in Guernsey. Br J Cancer 2000;82:1577-84.
85. Zhou J, Ng S, Adesanya-Famutya O, Anderson K, Bondy C. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14:1725-30.
86. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings S. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 1999;130:270-7.
87. Mady EA, Ramadan EE, Ossman AA. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers 2000;16:151-7.
88. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer 1984;54:2436-40.
89. Arlt W, Callies F, Van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341:1013-20.
90. Pérez-López FR. The aromatase inhibitor exemestane in the treatment of breast cancer. En: Sńchez Basurto C, editor. Proceedings of the XI International Congress of Senology. Bologna: Monduzzi Editore, 2000; p. 67-75.
91. Selim AG, El-Ayat G, Wells CA. Angrogen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. J Clin Pathol 2002;55:14-6.
92. Gitlin N, Korner P, Yang HM. Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: A meta-analysis of eight clinical trials. Menopause 1999;6:216-24.
93. Kokçu A, Cetiukaya MB, Yanik F, Alper T, Malatyalioglu. The comparison of effects of tibolone conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000;36:75-80.
94. Kloosterboer L. The tissue-specific mechanism of action of tibolone. Conferencia de Expertos: Setting a new standard in HRTL: the tissue-specific approach; 2001, junio 7-10; Budapest.
95. Laan E, Van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001;4:28-41.
96. Doren M, Rubig A, Coelingh Bennick HJ, Holzgreve W. Different effects on the androgen of postmenopausal women treated tibolone and continous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554-9.
97. Pérez-López FR. Breast cancer and hormone replacement therapy: putting the risk into context. En: Rozenbaum H, editor. First Congress of the Federation of National European Menopause Societies. Paris: Editions ESKA, 2001; p. 117-35.